Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand | Zendy

Punnee Pitisuttithum | Zendy; Peter B. Gilbert | Zendy; Marc Gurwith | Zendy; William L. Heyward | Zendy; Michael Martin | Zendy; Fritz van Griensven | Zendy; Dale J. Hu | Zendy; Jordan W. Tappero | Zendy; Kachit Choopanya | Zendy

Open Access

Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand

Author(s) -

Punnee Pitisuttithum,

Peter B. Gilbert,

Marc Gurwith,

William L. Heyward,

Michael Martin,

Fritz van Griensven,

Dale J. Hu,

Jordan W. Tappero,

Kachit Choopanya

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/508748

Subject(s) - medicine , placebo , vaccine trial , hiv vaccine , clinical endpoint , immunology , vaccine efficacy , randomized controlled trial , confidence interval , incidence (geometry) , viral load , vaccination , virology , clinical trial , human immunodeficiency virus (hiv) , pathology , alternative medicine , physics , optics

In Thailand, phase 1/2 trials of monovalent subtype B and bivalent subtype B/E (CRF01_AE) recombinant glycoprotein 120 human immunodeficiency virus type 1 (HIV-1) vaccines were successfully conducted from 1995 to 1998, prompting the first HIV-1 vaccine efficacy trial in Asia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research